Tommaso Ceccato

Dr. Tommaso Ceccato

Urology, University of Padua, Padua, Italy
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2022 in Applied Sciences
Verified
Journal Article
Open access
PDF file
LNLuigi Napolitano
Luigi Napolitano
LOLuca Orecchia
Luca Orecchia
CGCarlo Giulioni
Carlo Giulioni
Umberto CarbonaraUmberto Carbonara
Umberto Carbonara
GTGiovanni Tavella
Giovanni Tavella
RFRocco Simone Flammia
Rocco Simone Flammia
Renal cell carcinoma (RCC) is the most common form of kidney cancer with 403,262 diagnoses and 170,000 deaths worldwide in 2018. Although partial or radical nephrectomy can be considered a successful treatment in early-stage or localized RCC, in advanced-stage disease, there is a high risk of metastasis or recurrence with a significantly poorer prognosis. Metastatic RCC is generally resistant to both chemotherapy and radiotherapy, and, despite several novel therapeutic agents, disease progression and mortality rates remain high. It is necessary to identify new diagnostic and therapeutic strategies for the management of this cancer. Knowledge of microRNA (miRNA) has consistently increased in the last year. miRNAs play an important role in several biological processes, such as cell proliferation, differentiation, and cell death. Due to this, miRNAs have been identified as an important key in different diseases, especially in cancer, and several studies show miRNAs as attractive tools and targets for novel therapeutic approaches. Recently several miRNAs (including miR-22, miR-203, miR-301 and miR-193a-3p) have been linked to dysregulated molecular pathways involved with the proliferation of cancerous cells and resistance to therapeutic agents. In the present study, recent data from studies assessing the application of miRNAs as biomarkers, therapeutic targets, or modulators of response to treatment modalities in RCC patients are analyzed.

29 December 2024 in Urologia Journal
Verified
Journal Article
Closed access
TCTommaso Ceccato
Tommaso Ceccato
SBSimone Botti
Simone Botti
CTCarlo Tascini
Carlo Tascini
MLMassimiliano Lanzafame
Massimiliano Lanzafame
ABAnna Brugnolli
Anna Brugnolli
Tommaso CaiTommaso Cai
Tommaso Cai
Urinary tract infections (UTIs) are highly prevalent and frequently treated with antibiotics, making antimicrobial stewardship (AMS) crucial in this field to benefit both individual patients and society. This narrative review examines recent advancements in managing urinary tract infections, focusing on AMS and antimicrobial resistance (AMR). AMS is essential in urology, where antibiotics are frequently prescribed for UTI. AMS promotes optimal antibiotic use to improve patient outcomes, control AMR, and safeguard public health. Key AMS practices in urology include selecting antibiotics at the appropriate dose and duration, especially for uncomplicated UTIs, asymptomatic bacteriuria, and catheter-associated infections. Following evidence-based guidelines, such as those from EAU and the IDSA, helps prioritize narrow-spectrum antibiotics and discourage empirical broad-spectrum use. Regular audits and feedback on antibiotic use help align practices with AMS goals, reducing inappropriate prescriptions. Multidisciplinary AMS teams, including urologists, microbiologists, and pharmacists, enhance treatment precision and antibiotic optimization in complex cases. Reassessing antibiotic therapy based on culture results after 48–72 h enables clinicians to refine treatment, minimizing unnecessary broad-spectrum use and strengthening AMS efforts in urology. In conclusion, addressing AMR in urology requires a careful approach that combines evidence-based antibiotic use, attention to local resistance patterns, and patient-specific factors. Non-antibiotic strategies for recurrent UTI prevention, judicious catheter management, and tailored treatment for complex infections are key AMS components. Emerging technologies in diagnostics and precision medicine offer tools for targeted, personalized therapy, enhancing AMS efforts, and helping to reduce reliance on broad-spectrum antibiotics.

19 March 2025 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
AMAlberto Macchi
Alberto Macchi
MBMartina Bruniera
Martina Bruniera
SNSebastiano Nazzani
Sebastiano Nazzani
TCTommaso Ceccato
Tommaso Ceccato
CCClaudia Colbacchini
Claudia Colbacchini
NNNicola Nicolai
Nicola Nicolai

10 January 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
CVCristina Vocca
Cristina Vocca
Diana Marisol Abrego-GuandiqueDiana Marisol Abrego-Guandique
Diana Marisol Abrego-Guandique
Erika CioneErika Cione
Erika Cione
VRVincenzo Rania
Vincenzo Rania
GMGianmarco Marcianò
Gianmarco Marcianò
Luca GallelliLuca Gallelli
Luca Gallelli
Several studies have suggested that probiotics could play a role in the management of patients with chronic bacterial prostatitis (CBP). In this randomized, placebo-controlled clinical study, we evaluated the efficacy and safety of consumption of probiotics containing human Lactobacillus casei DG® as an add-on treatment in patients with clinical recurrences of CBP, through gut microbiota modification analysis. Enrolled patients with CBP were randomized to receive for 3 months probiotics containing human Lactobacillus casei DG® or placebo following 1 month treatment with ciprofloxacin. During the enrollment and follow-ups, urological examinations analyzed symptoms and quality of life, while microbiological tests analyzed gut and seminal microbiota. During the study, the development of adverse drug reactions was evaluated through the Naranjo scale. Twenty-four patients with CBP were recruited and treated for 3 months with placebo (n. 12) or with Lactobacillus casei DG® (n. 12). Lactobacillus casei DG® induced a significantly (p < 0.01) faster recovery of symptoms than placebo (2 days vs. 8 days) and an increased time free from symptoms (86 days vs. 42 days) without the occurrence of adverse events. In the probiotic group, the appearance of Lactobacilli after 30 days (T1) was higher vs. the placebo group, and a significant reduction in Corynebacterium, Peptoniphilus, Pseudomonas, Veillonella, Staphylococcus, and Streptococcus was also observed. These preliminary data suggest that in patients with CBP, the use of Lactobacillus casei DG after an antimicrobial treatment improves the days free of symptoms and the quality of life, without the development of adverse drug reactions.

5 July 2024 in Cancers
Verified
Journal Article
Open access
PDF file
Giuseppe ReitanoGiuseppe Reitano
Giuseppe Reitano
TCTommaso Ceccato
Tommaso Ceccato
SBSimone Botti
Simone Botti
MBMartina Bruniera
Martina Bruniera
SCSalvatore Carrozza
Salvatore Carrozza
FZFabio Zattoni
Fabio Zattoni
The management of high-risk prostate cancer (PCa) presents a significant clinical challenge, often necessitating treatment intensification due to the potential presence of micrometastases. While radical prostatectomy (RP) constitutes one of the primary treatment modalities, the integration of neoadjuvant and adjuvant therapies suggests a paradigm shift towards more aggressive treatment strategies, also guided by new imaging modalities like positron emission tomography using prostate-specific membrane antigen (PSMA-PET). Despite the benefits, treatment intensification raises concerns regarding increased side effects. This review synthesizes the latest evidence on perioperative treatment intensification and de-escalation for high-risk localized and locally advanced PCa patients eligible for surgery. Through a non-systematic literature review conducted via PubMed, Scopus, Web of Science, and ClinicalTrials.gov, we explored various dimensions of perioperative treatments, including neoadjuvant systemic therapies, adjuvant therapies, and the role of novel diagnostic technologies. Emerging evidence provides more support for neoadjuvant systemic therapies. Preliminary results from studies suggest the potential for treatments traditionally reserved for metastatic PCa to show apparent benefit in a non-metastatic setting. The role of adjuvant treatments remains debated, particularly the use of androgen deprivation therapy (ADT) and adjuvant radiotherapy in patients at higher risk of biochemical recurrence. The potential role of radio-guided PSMA lymph node dissection emerges as a cutting-edge approach, offering a targeted method for eradicating disease with greater precision. Innovations such as artificial intelligence and machine learning are potential game-changers, offering new avenues for personalized treatment and improved prognostication. The intensification of surgical treatment in high-risk PCa patients is a dynamic and evolving field, underscored by the integration of traditional and novel therapeutic approaches. As evidence continues to emerge, these strategies will refine patient selection, enhance treatment efficacy, and mitigate the risk of progression, although with an attentive consideration of the associated side effects.

5 July 2023 in Urology Case Reports
Verified
Journal Article
Open access
TCTommaso Ceccato
Tommaso Ceccato
MBMartina Bruniera
Martina Bruniera
MIMassimo Iafrate
Massimo Iafrate
FMFabrizio Dal Moro
Fabrizio Dal Moro
68-years-old man with end-stage-renal-disease (ESRD) and obesity presented with painful penile lesion: necrotic glans, extended till the penile base with the exposition of corpora cavernosa. Laboratory testing were normal and was afebrile so subsequently discharged with antibiotic therapy and medications. Clinical evaluation was suggestive for penile calciphylaxis, confirmed by seeing arterial calcifications at CT. Patient died one month later. Penile calciphylaxis is a rare life-threatening condition characterized by vascular calcification and fibrosis of medium and small arteries which causes an obstructive vasculopathy and tissue necrosis. Normalization of metabolic parameters, antibiotics, topical enzymatic debridement agents are recommended, considering the poor outcome.